BioNexus Gene Lab Corp. (BGLC) Free cash flow
- Free cash flow · 12 months (USD): Value $-853.60K; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -27.30%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-853.60K | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-846.57K − $7.04K ≈ $-853.60K |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -27.30% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-853.60K ÷ $3.13M × 100 ≈ -27.30% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-846.57K | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.33× | Operating cash flow / net income. Period ending 2026-06-30. $-846.57K ÷ $-2.58M ≈ 0.33× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -846.57K USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 7.04K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -853.60K USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 3.13M USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -2.58M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-853.60K | (m) | $-846.57K | $7.04K | (m) | $3.13M | (m) | $-2.58M | (m) | (m) | -27.30% | 0.33× |
| 2026-03-31 | $-1.19M | (m) | $-1.16M | $28.24K | (m) | $5.31M | (m) | $-2.90M | (m) | (m) | -22.41% | 0.40× |
| 2025-12-31 | $-1.88M | (m) | $-1.84M | $36.97K | (m) | $7.42M | (m) | $-2.98M | (m) | (m) | -25.26% | 0.62× |
| 2025-09-30 | $-2.76M | (m) | $-2.72M | $40.02K | (m) | $9.47M | (m) | $-2.30M | (m) | (m) | -29.17% | 1.18× |
| 2025-06-30 | $-3.32M | (m) | $-3.09M | $233.72K | (m) | $9.55M | (m) | $-2.93M | (m) | (m) | -34.76% | 1.05× |
| 2025-03-31 | $-3.24M | (m) | $-3.02M | $214.10K | (m) | $9.27M | (m) | $-2.12M | (m) | (m) | -34.92% | 1.43× |
| 2024-12-31 | $-2.46M | (m) | $-2.23M | $226.99K | (m) | $9.51M | (m) | $-1.60M | (m) | (m) | -25.88% | 1.40× |
| 2024-09-30 | $-2.50M | (m) | $-2.43M | $74.52K | (m) | $9.26M | (m) | $-941.56K | (m) | (m) | -27.01% | 2.58× |
| 2024-06-30 | (m) | (m) | $-1.87M | (m) | (m) | $9.18M | (m) | $-2.21M | (m) | (m) | (m) | 0.85× |
| 2024-03-31 | (m) | (m) | $-1.22M | (m) | (m) | $9.78M | (m) | $-2.66M | (m) | (m) | (m) | 0.46× |
| 2023-12-31 | $-1.30M | (m) | $-1.30M | $18.00 | (m) | $9.77M | (m) | $-2.63M | (m) | (m) | -13.32% | 0.50× |
| 2023-09-30 | $-736.23K | (m) | $-570.74K | $165.49K | (m) | $10.34M | (m) | $-3.09M | (m) | (m) | -7.12% | 0.18× |
| 2023-06-30 | $602.35K | (m) | $637.50K | $35.15K | (m) | $10.36M | (m) | $-562.69K | (m) | (m) | 5.81% | -1.13× |
| 2023-03-31 | $441.49K | (m) | $463.57K | $22.08K | (m) | $10.28M | (m) | $-442.10K | (m) | (m) | 4.30% | -1.05× |
| 2022-12-31 | $489.86K | (m) | $544.03K | $54.17K | (m) | $10.93M | (m) | $-355.97K | (m) | (m) | 4.48% | -1.53× |
| 2022-09-30 | $514.15K | (m) | $552.57K | $38.42K | (m) | $11.33M | (m) | $-109.75K | (m) | (m) | 4.54% | -5.03× |
| 2022-06-30 | $526.11K | (m) | $561.28K | $35.17K | (m) | $12.34M | (m) | $262.97K | (m) | (m) | 4.27% | 2.13× |
| 2022-03-31 | $-178.65K | (m) | $-144.11K | $34.55K | (m) | $12.94M | (m) | $429.89K | (m) | (m) | -1.38% | -0.34× |
| 2021-12-31 | $6.00K | (m) | $9.16K | $3.16K | (m) | $13.36M | (m) | $751.57K | (m) | (m) | 0.04% | 0.01× |
| 2021-09-30 | $35.44K | (m) | $458.64K | $423.20K | (m) | $14.24M | (m) | $488.17K | (m) | (m) | 0.25% | 0.94× |
| 2021-06-30 | $444.55K | (m) | $867.33K | $422.79K | (m) | $13.76M | (m) | $427.30K | (m) | (m) | 3.23% | 2.03× |
| 2021-03-31 | $1.22M | (m) | $1.65M | $422.12K | (m) | $11.77M | (m) | $363.20K | (m) | (m) | 10.39% | 4.53× |
| 2020-12-31 | $131.06K | (m) | $552.68K | $421.62K | (m) | $11.39M | (m) | $1.09M | (m) | (m) | 1.15% | 0.51× |
| 2020-09-30 | $-194.78K | (m) | $-213.27K | $-18.49K | (m) | $83.06K | (m) | $-267.10K | (m) | (m) | -234.50% | 0.80× |
| 2020-06-30 | $-191.70K | (m) | $-213.72K | $-22.02K | (m) | $83.76K | (m) | $-229.09K | (m) | (m) | -228.86% | 0.93× |
| 2020-03-31 | (m) | (m) | $-209.30K | (m) | (m) | (m) | (m) | $-232.96K | (m) | (m) | (m) | 0.90× |
| 2019-12-31 | $-204.46K | (m) | $-217.27K | $-12.82K | (m) | $126.95K | (m) | $-246.47K | (m) | (m) | -161.05% | 0.88× |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-234.46K | (m) | $-274.08K | $-39.62K | (m) | $212.33K | (m) | $26.45K | (m) | (m) | -110.42% | -10.36× |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |